Zai Lab Ltd (NASDAQ:ZLAB) has been assigned a consensus rating of “Buy” from the ten brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $45.45.
A number of analysts have recently commented on the company. Leerink Swann set a $48.00 target price on Zai Lab and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Bank of America assumed coverage on Zai Lab in a research note on Friday, July 12th. They issued a “buy” rating and a $43.00 target price on the stock. Zacks Investment Research upgraded Zai Lab from a “sell” rating to a “hold” rating in a research note on Saturday, September 14th. Macquarie assumed coverage on Zai Lab in a research note on Friday, July 5th. They issued an “outperform” rating and a $36.54 target price on the stock. Finally, China Renaissance Securities assumed coverage on Zai Lab in a research note on Wednesday, September 4th. They issued a “buy” rating on the stock.
Shares of ZLAB traded down $0.08 during mid-day trading on Friday, reaching $34.04. The company had a trading volume of 82,600 shares, compared to its average volume of 133,924. Zai Lab has a 52-week low of $15.15 and a 52-week high of $38.44. The stock has a market capitalization of $1.98 billion, a P/E ratio of -12.89 and a beta of 1.32. The stock has a 50 day moving average of $33.28 and a two-hundred day moving average of $31.91.
About Zai Lab
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
Read More: What is a bull market?
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.